Baird raised the firm’s price target on iRhythm to $135 from $125 and keeps an Outperform rating on the shares. The firm said the company reiterated its 2024 outlook and provided more insight into some longer-term growth opportunities, namely sleep apnea.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IRTC:
- iRhythm Technologies Announces Fourth Quarter and Full Year 2023 Financial Results
- Irhythm Technologies (IRTC) Q4 Earnings Cheat Sheet
- iRhythm Technologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
- SHAREHOLDER ALERT: Potential Recovery for iRhythm Technologies, Inc. (IRTC) Investors
- iRhythm reports closing of five-year debt facility
